🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
The efficacy and safety of HAIC combined with tyrosine kinase inhibitor and...
Status
Unknown
Location
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Start Date
2021-11-05
Trial ID
NCT05135364
Treatments Being Tested
Hepatocellular carcinoma (HCC) is a common global malignancy. In China, the...
Status
Active Not Recruiting
Location
Harbin Medical University Cancer Hospital, No. 150 Haping Road, Nangang District, Harbin, Heilongjiang Province, China
Start Date
2026-05-13
Trial ID
NCT07645209
Treatments Being Tested
This retrospective multicenter study aims to evaluate whether radiographic ...
Status
Completed
Location
The First Affiliated Hospital of Sun Yat-sen University
Start Date
2018-06-01
Trial ID
NCT07449065
Transarterial chemoembolization (TACE) is widely used for unresectable hepa...
Status
Unknown
Location
Shandong Cancer Hospital and Institute
Start Date
2012-05
Trial ID
NCT01556815
Treatments Being Tested
To evaluate the effectiveness of TACE combined with immunotherapy and targe...
Status
Unknown
Location
the Qianfoshan Hospital
Start Date
2024-01-01
Trial ID
NCT06205732
Treatments Being Tested
Hepatocellular carcinoma (HCC) is the fourth most common cause of cancer-re...
Status
Completed
Location
Sichuan Cancer Hospital and Research Institute
Start Date
2020-09-14
Trial ID
NCT04518852
Treatments Being Tested
The study is a multicenter phase III randomized trial. The purpose is to in...
Status
Completed
Location
The First Affiliated Hospital of Sun Yat-sen University
Start Date
2019-10-02
Trial ID
NCT04103398
Treatments Being Tested
This multicenter prospective nonrandomized study is to evaluate the efficac...
Status
Unknown
Location
Xijing Hospital of digestive disease, Fourth Military Medical University
Start Date
2015-08
Trial ID
NCT02529761
Toripalimab is a programmed cell death protein 1 antibody.This is an open-l...
Status
Unknown
Location
Zhongshan Hospital
Start Date
2019-08-01
Trial ID
NCT04926532
Treatments Being Tested
This study will combine two therapies to treat patients with unresectable h...
Status
Completed
Location
The Johns Hopkins Hospital
Start Date
2009-02
Trial ID
NCT00844883
Treatments Being Tested